Navoximod

• Description:

  Navoximod (GDC-0919; NLG- 919) is a potent IDO (indoleamine- (2,3) -dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM.

• Product Name Alternative:

  GDC-0919; NLG-​919

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319

• Target:

  Indoleamine 2,3-Dioxygenase (IDO)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Navoximod.html

• Purity:

  99.99

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O[C@H] (CC1) CC[C@]1 ([H]) [C@H] (O) C[C@@H]2N3C (C4=C2C (F) =CC=C4) =CN=C3

• Molecular Formula:

  C18H21FN2O2

• Molecular Weight:

  316.37

• Precautions:

  H315, H319

• References & Citations:

  [1]Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO) -pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.|[2]Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21.|[3]Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  IDO

• CAS Number:

  1402837-78-8